Withanone-Rich Combination of Ashwagandha Withanolides Restricts Metastasis and Angiogenesis through hnRNP-K
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gao, Ran | - |
dc.contributor.author | Shah, Navjot | - |
dc.contributor.author | Lee, Jung-Sun | - |
dc.contributor.author | Katiyar, Shashank P. | - |
dc.contributor.author | Li, Ling | - |
dc.contributor.author | Oh, Eonju | - |
dc.contributor.author | Sundar, Durai | - |
dc.contributor.author | Yun, Chae-Ok | - |
dc.contributor.author | Wadhwa, Renu | - |
dc.contributor.author | Kaul, Sunil C. | - |
dc.date.accessioned | 2021-08-02T18:28:09Z | - |
dc.date.available | 2021-08-02T18:28:09Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2014-12 | - |
dc.identifier.issn | 1535-7163 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/25704 | - |
dc.description.abstract | Ashwagandha is an important herb used in the Indian system of traditional home medicine, Ayurveda. Alcoholic extract (i-Extract) from its leaves and its component, withanone, were previously shown to possess anticancer activity. In the present study, we developed a combination of withanone and withaferin A, major withanolides in the i-Extract, that retained the selective cancer cell killing activity and found that it also has significant antimigratory, -invasive, and -angiogenic activities, in both in vitro and in vivo assays. Using bioinformatics and biochemical approaches, we demonstrate that these phytochemicals caused downregulation of migration-promoting proteins hnRNP-K, VEGF, and metalloproteases and hence are candidate natural drugs for metastatic cancer therapy. (C)2014 AACR. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | AMER ASSOC CANCER RESEARCH | - |
dc.title | Withanone-Rich Combination of Ashwagandha Withanolides Restricts Metastasis and Angiogenesis through hnRNP-K | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yun, Chae-Ok | - |
dc.identifier.doi | 10.1158/1535-7163.MCT-14-0324 | - |
dc.identifier.scopusid | 2-s2.0-84918562005 | - |
dc.identifier.wosid | 000346132900015 | - |
dc.identifier.bibliographicCitation | MOLECULAR CANCER THERAPEUTICS, v.13, no.12, pp.2930 - 2940 | - |
dc.relation.isPartOf | MOLECULAR CANCER THERAPEUTICS | - |
dc.citation.title | MOLECULAR CANCER THERAPEUTICS | - |
dc.citation.volume | 13 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 2930 | - |
dc.citation.endPage | 2940 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | NUCLEAR RIBONUCLEOPROTEIN K | - |
dc.subject.keywordPlus | BREAST-CANCER CELLS | - |
dc.subject.keywordPlus | GROWTH-FACTOR VEGF | - |
dc.subject.keywordPlus | MATRIX METALLOPROTEINASES | - |
dc.subject.keywordPlus | MOLECULAR-DYNAMICS | - |
dc.subject.keywordPlus | ENDOTHELIAL-CELLS | - |
dc.subject.keywordPlus | SIGNALING PATHWAY | - |
dc.subject.keywordPlus | LEAF EXTRACT | - |
dc.subject.keywordPlus | WITHAFERIN | - |
dc.subject.keywordPlus | ACTIVATION | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.